在高风险的MDS中药理学进展:一场艰苦的战斗
1Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven.
Expert opinion on pharmacotherapy
|March 10, 2026
概括
高风险的骨髓质疏松症候群 (MDS) 难以治疗,目前的疗法有效性有限. 研究中的治疗方法在III期试验中遇到了困难,这凸显了需要更好的治疗策略的需要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓质综合征 (MDS) 是一种具有无效血液形成和急性骨髓白血病 (AML) 风险的克隆性骨髓质恶性瘤.
- 高风险的MDS在没有干细胞移植的情况下仍然在很大程度上无法治愈.
- 目前的管理依赖于适度有效的低甲基化剂.
研究的目的:
- 审查研究药物治疗在高风险的MDS的历史和演变.
- 确定将早期试验成功转化为III期试验的挑战.
- 为未来MDS治疗中的治疗突破提供信息.
主要方法:
- 对较高风险的MDS进行历史和当前的试验性药物治疗的审查.
- 对临床试验结果的分析,重点关注III期失败.
- 检查分子分析和下一代测序的进展.
主要成果:
- 尽管在分子分析方面取得了进展,但在高风险的MDS中,有针对性的疗法是有限的.
- 许多早期试验显示出有希望的结果,但III期试验经常失败.
- 生物复杂性,异质性和试验设计挑战导致失败.
结论:
- 将高风险MDS的试验疗法的早期成功转化为III期试验仍然是一个重大障碍.
- 进一步了解MDS生物学和改进试验设计对于未来的治疗进展至关重要.
- 对于高风险的MDS,迫切需要开发新的和有效的治疗方法.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Drug Therapy
361
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
361
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59


